Wednesday 03 July 2024
Internal Reference Number: FOI_7885
Date Request Received: 12/04/2024 00:00:00
Date Request Replied To: 08/05/2024 00:00:00
This response was sent via: By Email
Request Summary: Multiple Myeloma
Request Category: Companies
| Question Number 1: Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. | |
| Answer To Question 1: There are 69 separate patients | |
| Question Number 2: Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Bortezomib [Velcade] monotherapy or with dexamethasone • Bortezomib, thalidomide and dexamethasone [VTD] • Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) • Carfilzomib [Kyprolis] and dexamethasone • Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone • Daratumumab [Darzalex] monotherapy • Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) • Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) • Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) • Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) • Lenalidomide [Revlmid] monotherapy • Lenalidomide [Revlimid] and dexamethasone • Pomalidomide [Imnovid] and dexamethasone • Selinexor and dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapyThanks very much. | |
| Answer To Question 2: • Belantamab Mafodotin [Blenrep] < 5 patients • Bortezomib [Velcade] monotherapy or with dexamethasone 0 patients • Bortezomib, thalidomide and dexamethasone [VTD] 0 patients • Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) <5 patients • Carfilzomib [Kyprolis] and dexamethasone 0 patients • Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone <5 patients • Daratumumab [Darzalex] monotherapy 0 patients • Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) 17 patients • Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) 9 patients • Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone 8 patients • Elranatamab 0 patients • Idecabtagene vicleucel [Abecma] 0 patients • Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) < 5 patients • Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) 12 patients • Lenalidomide [Revlmid] monotherapy 18 patients • Lenalidomide [Revlimid] and dexamethasone 0 patients • Pomalidomide [Imnovid] and dexamethasone 0 patients • Selinexor and dexamethasone 0 patients • Talquetamab 0 patients • Teclistamab [Tecvayli] 0 patients • Any other systemic anti-cancer therapy No | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
